BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19789372)

  • 1. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
    Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
    J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
    Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
    Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
    Granfors MT; Backman JT; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
    Henney HR; Fitzpatrick A; Stewart J; Runyan JD
    Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
    Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
    Backman JT; Schröder MT; Neuvonen PJ
    Eur J Clin Pharmacol; 2008 Jan; 64(1):17-24. PubMed ID: 17955229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
    Shah J; Wesnes KA; Kovelesky RA; Henney HR
    Clin Ther; 2006 Sep; 28(9):1308-17. PubMed ID: 17062304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
    Shellenberger MK; Groves L; Shah J; Novack GD
    Drug Metab Dispos; 1999 Feb; 27(2):201-4. PubMed ID: 9929503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical survey of tizanidine-induced adverse effects--impact of concomitant drugs providing cytochrome P450 1A2 modification--].
    Momo K; Homma M; Matsumoto S; Sasaki T; Kohda Y
    Yakugaku Zasshi; 2013; 133(2):275-81. PubMed ID: 23370523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
    Backman JT; Granfors MT; Neuvonen PJ
    Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
    Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
    J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
    Henney HR; Runyan JD
    Int J Clin Pract; 2008 Feb; 62(2):314-24. PubMed ID: 18199279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
    Wei X; Dai R; Zhai S; Thummel KE; Friedman FK; Vestal RE
    J Pharmacol Exp Ther; 1999 May; 289(2):853-8. PubMed ID: 10215663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF
    Zhang W; McIntyre C; Riehl T; Forbes H; Bertran E; Choi HJ; Lee DH; Lee J
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):651-658. PubMed ID: 32311241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of clonidine in rabbit plasma by HPLC-MS].
    Ke GM; Zhang EH; Wang L; Zhang Q; Du HG; Guo HY
    Yao Xue Xue Bao; 2004 May; 39(5):367-9. PubMed ID: 15338881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.